Insider · CIK 0001684531
James Mulay
Files at CGON (CG Oncology, Inc.). First filing Sep 8, 2025, latest Jul 14, 2026.
In brief
James Mulay files SEC Form 4 as director at CGON (CG Oncology, Inc.). Since Sep 8, 2025, James Mulay has reported 0 open-market buys worth $0 and 9 open-market sells worth $6.3M, the latest filed on Jul 14, 2026.
A track record needs three past buys with six months of prices behind them; James Mulay has 0, so none is measured yet.
The newest scored trade: sold $1.8M of CGON on Jul 10, 2026, filed Jul 14, 2026, scored 33 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $3.8M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGON: CG Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | CG Oncology, Inc. | $1.8M 24,165 shares | -100% | +214% from low0% from high | |
| 18Weak | CG Oncology, Inc. | $118k 1,964 shares | -300% | +149% from low-20% from high | |
| 25Weak | CG Oncology, Inc. | $1.1M 15,600 shares | -100% | +260% from low0% from high | |
| 10Weak | CG Oncology, Inc. | $125k 1,964 shares | -300% | +323% from low0% from high | |
| 19Weak | CG Oncology, Inc. | $585k 11,145 shares | -1704% | +248% from low0% from high | |
| 21Weak | CG Oncology, Inc. | $260k 5,903 shares | -100% | +185% from low0% from high | |
| 26Weak | CG Oncology, Inc. | $500k 12,755 shares | -100% | +151% from low-2% from high | |
| 31Weak | CG Oncology, Inc. | $885k 22,686 shares | -119% | +149% from low-3% from high | |
| 38Weak | CG Oncology, Inc. | $852k 27,015 shares | -100% | +112% from low-17% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 10, 2026 | CGON CG Oncology, Inc. | 20,237 0.02% of outstanding | $1.5M | Jul 10, 2026 | $1.3M |
| Jul 1, 2026 | CGON CG ONCOLOGY INC | 3,928 0.00% of outstanding | $279k | Jul 1, 2026 | $1.3M |
| Apr 17, 2026 | CGON CG Oncology, Inc. | 17,564 0.02% of outstanding | $1.2M | Apr 17, 2026 | $125k |
| Jan 9, 2026 | CGON CG Oncology, Inc. | 13,109 0.02% of outstanding | $550k | Jan 9, 2026 | none |
| Oct 9, 2025 | CGON CG ONCOLOGY INC | 6,557 0.01% of outstanding | $267k | Oct 9, 2025 | $2.2M |
| Sep 18, 2025 | CGON CG Oncology, Inc. | 35,441 0.05% of outstanding | $1.3M | Sep 18, 2025 | $852k |
| Sep 5, 2025 | CGON CG ONCOLOGY INC | 27,015 0.04% of outstanding | $836k | Sep 5, 2025 | none |
Transactions
Every row this insider has filed, 44 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +24,165 | $26.63 | $644k | 24,165 | Jul 14, 2026 |
| Jul 10, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -24,165 | $75.16 | $1.8M | 0 | Jul 14, 2026 |
| Jul 10, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -24,165 | $0.00 | $0 | 0 | Jul 14, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +654 | $3.72 | $2,433 | 654 | Jun 16, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -654 | $60.12 | $39k | 0 | Jun 16, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +1,310 | $12.59 | $16k | 1,310 | Jun 16, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -1,310 | $60.12 | $79k | 0 | Jun 16, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -654 | $0.00 | $0 | 0 | Jun 16, 2026 |
| Jun 15, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -1,310 | $0.00 | $0 | 2,620 | Jun 16, 2026 |
| Jun 4, 2026 | CGON CG Oncology, Inc. | AGrant or award Director Stock Option (right to buy)derivative | +9,354 | $0.00 | $0 | 9,354 | Jun 5, 2026 |
| Apr 17, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +15,600 | $36.63 | $571k | 15,600 | Apr 20, 2026 |
| Apr 17, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -15,600 | $73.01 | $1.1M | 0 | Apr 20, 2026 |
| Apr 17, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -15,600 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +654 | $3.72 | $2,433 | 654 | Mar 17, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -654 | $63.50 | $42k | 0 | Mar 17, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +1,310 | $12.59 | $16k | 1,310 | Mar 17, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -1,310 | $63.50 | $83k | 0 | Mar 17, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -654 | $0.00 | $0 | 654 | Mar 17, 2026 |
| Mar 16, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -1,310 | $0.00 | $0 | 3,930 | Mar 17, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +654 | $3.72 | $2,433 | 654 | Jan 13, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -654 | $44.16 | $29k | 0 | Jan 13, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +10,491 | $12.59 | $132k | 10,491 | Jan 13, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -10,491 | $52.99 | $556k | 0 | Jan 13, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -654 | $0.00 | $0 | 1,308 | Jan 13, 2026 |
| Jan 9, 2026 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -10,491 | $0.00 | $0 | 5,240 | Jan 13, 2026 |
| Oct 9, 2025 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +5,903 | $3.72 | $22k | 5,903 | Oct 10, 2025 |
| Oct 9, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -5,903 | $43.99 | $260k | 0 | Oct 10, 2025 |
| Oct 9, 2025 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -5,903 | $0.00 | $0 | 1,962 | Oct 10, 2025 |
| Sep 29, 2025 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +12,755 | $1.82 | $23k | 12,755 | Sep 30, 2025 |
| Sep 29, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -12,755 | $39.19 | $500k | 0 | Sep 30, 2025 |
| Sep 29, 2025 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -12,755 | $0.00 | $0 | 0 | Sep 30, 2025 |
| Sep 18, 2025 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +19,112 | $1.82 | $35k | 19,112 | Sep 22, 2025 |
| Sep 18, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -19,112 | $39.01 | $746k | 0 | Sep 22, 2025 |
| Sep 19, 2025 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +3,574 | $1.82 | $6,505 | 3,574 | Sep 22, 2025 |
| Sep 19, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -3,574 | $38.99 | $139k | 0 | Sep 22, 2025 |
| Sep 18, 2025 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -19,112 | $0.00 | $0 | 16,329 | Sep 22, 2025 |
| Sep 19, 2025 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -3,574 | $0.00 | $0 | 12,755 | Sep 22, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | MOption exercise Common Stock10b5-1 | +27,015 | $0.60 | $16k | 27,015 | Sep 8, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -12,342 | $30.47 | $376k | 14,673 | Sep 8, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -4,095 | $31.42 | $129k | 10,578 | Sep 8, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -7,465 | $32.64 | $244k | 3,113 | Sep 8, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | SOpen-market sale Common Stock10b5-1 | -3,113 | $33.22 | $103k | 0 | Sep 8, 2025 |
| Sep 5, 2025 | CGON CG Oncology, Inc. | MOption exercise Director Stock Option (right to buy)derivative10b5-1 | -27,015 | $0.00 | $0 | 0 | Sep 8, 2025 |
| Jun 5, 2025 | CGON CG Oncology, Inc. | AGrant or award Director Stock Option (right to buy)derivative10b5-1 | +24,165 | $0.00 | $0 | 24,165 | Jun 6, 2025 |
Questions about James Mulay
Answered from the filings on this page, as of the latest one.
Is James Mulay buying or selling?
In the last 12 months James Mulay reported 0 open-market buys worth $0 and 5 open-market sells worth $3.8M on SEC Form 4; the latest was sold $1.8M of CGON on Jul 10, 2026. Grants, option exercises and tax withholding are not counted.
How did James Mulay's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Mulay has 0.
Where does James Mulay file Form 4?
James Mulay has filed Form 4 at CGON (CG Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.